Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.
Article Details
- CitationCopy to clipboard
Smolders EJ, de Kanter CT, de Knegt RJ, van der Valk M, Drenth JP, Burger DM
Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.
Clin Pharmacokinet. 2016 Dec;55(12):1471-1494. doi: 10.1007/s40262-016-0407-2.
- PubMed ID
- 27317413 [ View in PubMed]
- Abstract
Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed since the development and licensing of new potent direct-acting antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes. Additionally, these DAAs are both substrates and inhibitors of drug transporters, which makes the DAAs both possible victims or perpetrators of drug-drug interactions (DDIs). There is a high prevalence of mental illnesses such as depression or psychosis in HCV-infected patients; therefore, psychoactive medications are frequently co-administered with DAAs. The majority of these psychoactive medications are also metabolized by CYP enzymes but remarkably little information is available on DDIs between psychoactive medications and DAAs. Hence, the aim of this review is to provide an overview of the interaction mechanisms between DAAs and psychoactive agents. In addition, we describe evidenced-based interactions between DAAs and psychoactive drugs and identify safe options for the simultaneous treatment of mental illnesses and chronic HCV infection.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Clorazepic acid Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails - Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Trazodone P-glycoprotein 1 Protein Humans UnknownInducerDetails - Drug Reactions
Reaction Details
